Gene-editing therapy shows promise against advanced colorectal cancer
The CRISPR/Cas9 gene-editing technique has shown promise in fighting advanced colorectal cancer, according to results of the first-in-human clinical trial published in The Lancet Oncology.
The trial shows encouraging signs of the safety and potential effectiveness of the treatment against metastatic gastrointestinal (GI) cancers.
In the study, researchers used CRISPR/Cas9 gene-editing to modify a type of immune cell called tumour-infiltrating lymphocytes (TILs).
They deactivated a gene called CISH and found that modified TILs were better able to recognise and attack cancer cells.
"Despite many advances in understanding the genomic drivers and other factors causing cancer, with few exceptions, stage IV colorectal cancer remains a largely incurable disease," said Emil Lou, a gastrointes...